These results highlight that the future of prostate cancer diagnosis might rely on the combination of a panel of markers based on PSA forms that can give accurate molecular diagnosis and staging and indicate the likelihood of aggressive behavior. This evidence concerns the gene KLK3 and prostate carcinoma.